Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
NCT00504400
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Type 2 Idiopathic Macular Telangiectasia
Interventions
DRUG:
Intravitreal injection ranibizumab
Sponsor
University Hospital, Bonn
Collaborators
[object Object]